Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Breakspear Medical
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===2012 Advertising Standards Authority ruling=== In 2012 the British [[Advertising Standards Authority]] (ASA) that regulates advertising ruled against Breakspear Medical for claiming [[chelation therapy]] was an effective treatment for patients with various diseases including [[chronic fatigue syndrome]]. The ASAc stated:<ref>[https://jdc325.wordpress.com/2012/05/16/asa-gmc-breakspear-monro/ The Breakspear Hospital and Jean Monro v the ASA and the GMC]</ref><ref name="BreakspearASA2012">{{Cite web | url = https://www.asa.org.uk/Rulings/Adjudications/2012/5/Breakspear-Medical-Group-Ltd/SHP_ADJ_175882.aspx | title = ASA Ruling on Breakspear Medical Group Ltd | date = May 16, 2012 | website = [[Advertising Standards Authority]] | access-date = 2022-06-06|quote=With regard to the claim to treat chronic fatigue syndrome, Breakspear provided us with a paper on a chelating treatment called D-Penicillamine. We also noted Breakspear's argument that there had been some research which had indicated that there was an association between heavy metal exposure and chronic fatigue syndrome. However, we did not see in the paper a direct link between chelation therapy and the effective treatment of chronic fatigue syndrome. Breakspear also provided us with a paper on the link between mercury toxicity and a range of conditions, including chronic fatigue syndrome. We noted however that where DMSA chelation therapy had been used exclusively to treat chronic fatigue syndrome by removing mercury from the body, no effect was demonstrated and we therefore did not consider that this part of the claim was substantiated.}}</ref> {{Quote frame|text=With regard to the claim to treat chronic fatigue syndrome, Breakspear provided us with a paper on a chelating treatment called D-Penicillamine. We also noted Breakspear's argument that there had been some research which had indicated that there was an association between heavy metal exposure and chronic fatigue syndrome. However, we did not see in the paper a direct link between chelation therapy and the effective treatment of chronic fatigue syndrome. Breakspear also provided us with a paper on the link between mercury toxicity and a range of conditions, including chronic fatigue syndrome. We noted however that where DMSA chelation therapy had been used exclusively to treat chronic fatigue syndrome by removing mercury from the body, no effect was demonstrated and we therefore did not consider that this part of the claim was substantiated.<ref name="BreakspearASA2012"/> | author = Advertising Standards Authority (2022)}}
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs